Byondis’ Lead IO Therapy Scheduled to Enter Phase I Study This Year NIJMEGEN, Netherlands, April 17, 2023 /PRNewswire/ — Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that the Journal for ImmunoTherapy of Cancer…
